# EDGAR Filing Document

**Accession Number:** 0001395064
**File Stem:** 0001395064-25-000138
**Filing Date:** 2025-9
**Character Count:** 16692
**Document Hash:** a96598c120aec9c87958360a4da75768
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001395064-25-000138.hdr.sgml**: 20250919

**ACCESSION NUMBER**: 0001395064-25-000138

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20250919

**DATE AS OF CHANGE**: 20250919

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** HilleVax, Inc.
- **CENTRAL INDEX KEY:** 0001888012
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-93640
- **FILM NUMBER:** 251324925

**BUSINESS ADDRESS:**
- **STREET 1:** 321 HARRISON AVE, SUITE 500
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02118
- **BUSINESS PHONE:** (617) 213-5054

**MAIL ADDRESS:**
- **STREET 1:** 321 HARRISON AVE, SUITE 500
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02118
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** TAKEDA PHARMACEUTICAL CO LTD
- **CENTRAL INDEX KEY:** 0001395064
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU
- **CITY:** TOKYO
- **STATE:** M0
- **ZIP:** 103-8668
- **BUSINESS PHONE:** 81332782111

**MAIL ADDRESS:**
- **STREET 1:** 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU
- **CITY:** TOKYO
- **STATE:** M0
- **ZIP:** 103-8668

## Ex-1

**Exhibit 1**

**JOINT FILING AGREEMENT**

In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13D (including any and all amendments thereto) with respect to the Common Stock of HilleVax, Inc. and further agree to the filing of this agreement as an Exhibit thereto. In addition, each party to this Agreement expressly authorizes each other party to this Agreement to file on its behalf any and all amendments to such Statement on Schedule 13D.

Dated: September 19, 2025

---

| |
|:---|
| **TAKEDA PHARMACEUTICAL COMPANY LIMITED**<br>By: /s/Paul Sundberg<br>Name: Paul Sundberg<br>Title: Authorized Signatory  |
| <br>**TAKEDA VACCINES, INC.**<br>By:/s/ Max Heuer<br>Name: Max Heuer<br>Title: Authorized Signatory |

---

## Ex-1.A

**SCHEDULE A**

**DIRECTORS AND EXECUTIVE OFFICERS OF THE REPORTING PERSONS**

**<u>Takeda Pharmaceutical Company Limited</u>**

&nbsp;&nbsp;&nbsp;&nbsp;The name, business address, title and present principal occupation or employment of each of the directors and executive officers of Takeda Pharmaceutical Company Limited ("Takeda") are set forth below. If no address is given, the business address is 1-1, Nihonbashi-Honcho 2-Chome, Chuo-Ku, Tokyo, M0 103-8668, Japan.

---

| | | |
|:---|:---|:---|
| **<u>Director</u>** | **<u>Principal Occupation</u>** | **<u>Citizenship</u>** |
| Christophe Weber | Representative Director, President and Chief Executive Officer of Takeda | France |
| Milano Furuta | Director and Chief Financial Officer of Takeda | Japan |
| Andrew S. Plump, M.D., Ph.D. | Director and President, Research and Development of Takeda | US |
| Masami Iijima  | Counselor of Mitsui & Co., Ltd | Japan |
| Ian Clark | Former CEO and Director of Genentech Inc. | US |
| Steven Gillis, Ph.D. | Managing Director at ARCH Venture Partners | US |
| Emiko Higashi | Managing Director of Tomon Partners, LLC | Japan |
| John Maraganore, Ph.D. | Former Director and CEO of Alnylam Pharmaceuticals, Inc. | US |
| Michel Orsinger | Former Member of Global Management Team of Johnson & Johnson | Switzerland |
| Miki Tsusaka | President of Microsoft Japan Co., Ltd. | Japan |
| Koji Hatsukawa | Former CEO of PricewaterhouseCoopers Arata | Japan |
| Jean-Luc Butel | Global Healthcare Advisor, President of K8 Global Pte. Ltd | Singapore |
| Yoshiaki Fujimori | Senior Executive Advisor of CVC Japan | Japan |
| Kimberly A. Reed | Former Chairman of the Board of Directors, President, and CEO of Export-Import Bank of the United States | US |

---

------

<br> <br> <br>

---

| | | |
|:---|:---|:---|
| **<u>Executive Officer</u>** | **<u>Title - Principal Occupation</u>** | **<u>Citizenship</u>** |
| Christophe Weber | Representative Director, President and Chief Executive Officer  | France |
| Milano Furuta | Director and Chief Financial Officer  | Japan |
| Andrew S. Plump, M.D., Ph.D. | Director and President, Research and Development  | US |
| Akiko Amakawa | Corporate Strategy Officer & CEO Chief of Staff | Japan |
| Asuka Miyabashira | President, Japan Pharma Business Unit | Japan |
| Gabriele Ricci | Chief Data & Technology Officer | Italy |
| Giles Platford | President, Plasma-Derived Therapies Business Unit | UK |
| Elaine Shannon | Global Quality Officer | Ireland |
| Julie Kim | President, US Business Unit, US Country Head and Interim Head of Global Portfolio Division | US |
| Lauren Duprey | Chief Human Resources Officer | US |
| Marcello Agosti | Global Business Development Officer | Italy |
| Mwana Lugogo | Chief Ethics & Compliance Officer | Kenya |
| Natalie Furney | Global General Counsel | US |
| Takako Ohyabu | Chief Global Corporate Affairs & Sustainability Officer | Japan |
| Teresa Bitetti | President, Global Oncology Business Unit | US |
| Thomas Wozniewski, Ph.D. | Global Manufacturing & Supply Officer | Germany |

---

**<u>Takeda Vaccines, Inc.</u>**

&nbsp;&nbsp;&nbsp;&nbsp;The name, business address, title and present principal occupation or employment of each of the directors and executive officers of Takeda Vaccines, Inc. ("Takeda Vaccines") are set forth below. If no address is given, the business address is 75 Sidney Street, Cambridge, Massachusetts 02139.

---

| | | |
|:---|:---|:---|
| **<u>Director</u>** | **<u>Principal Occupation</u>** | **<u>Citizenship</u>** |
| Derek Wallace | President, Vaccines Business Unit | UK |

---

---

| | | |
|:---|:---|:---|
| **<u>Executive Officer</u>** | **<u>Title - Principal Occupation</u>** | **<u>Citizenship</u>** |
| Derek Wallace | President | UK |
| Matthew Symonds | Treasurer | US |
| Jason Baranski | Secretary | US |
| Paul Sundberg<br>Max Heuer  | Assistant Secretary<br>Assistant Secretary | US<br>US |
| Scott Dessing | Assistant Treasurer | US |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 1)**

**HILLEVAX, INC.**

*(Name of Issuer)*

**Common Stock, par value $0.0001 per share**

*(Title of Class of Securities)*

**43157M102**

*(CUSIP Number)*

**Paul Sundberg**<br>1-1, Nihonbashi-Honcho 2-Chome Chuo-Ku<br>Tokyo M0 103-8668<br>81-3-3278-2111

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**09/17/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **43157M102** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Takeda Pharmaceutical Company Limited** | Name of reporting person<br>**Takeda Pharmaceutical Company Limited** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**M0** | Citizenship or place of organization<br>**M0** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**0.00** | Aggregate amount beneficially owned by each reporting person<br>**0.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.0%** | Percent of class represented by amount in Row (11)<br>**0.0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

| **CUSIP No.** | **43157M102** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Takeda Vaccines Inc.** | Name of reporting person<br>**Takeda Vaccines Inc.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**0.00** | Aggregate amount beneficially owned by each reporting person<br>**0.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.0%** | Percent of class represented by amount in Row (11)<br>**0.0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.0001 per share

**(b) Name of Issuer:**
HILLEVAX, INC.

**(c) Address of Issuer's Principal Executive Offices:**
321 HARRISON AVE, SUITE 500, BOSTON, MA, 02118

This Amendment No. 1 ("Amendment") to Schedule 13D (the "Statement") amends the Statement originally filed with the U.S. Securities and Exchange Commission (the "SEC") on May 9, 2022, with respect to the common stock, par value $0.0001 per share (the "Common Stock") per share of Hillevax, Inc., a Delaware corporation (the "Company"), whose principal executive offices are located at 321 Harrison Avenue, Boston, Massachusetts 02118. Capitalized terms used herein and not defined herein have the meanings ascribed thereto in the Statement. Except as set forth below, all previous Items and disclosures set forth in the Statement remain unchanged.

**Item 4. Purpose of Transaction**

The cash tender offer (the "Tender Offer") by XOMA Royalty Corporation, a Nevada corporation ("Parent") and XRA 4 Corp., a Delaware corporation ("Merger Sub") and a wholly owned subsidiary of Parent, to purchase all of the outstanding shares of the Common Stock (collectively, the "Shares" and each, a "Share") at an offer price of (i) $1.95 per Share and (ii) one non- transferable contractual contingent value right ( "CVR"), expired as scheduled at one minute after 11:59 p.m., Eastern Time, on September 15, 2025 (the "Expiration Time") and closing of the Tender Offer was announced September 17, 2025. As all conditions to the Tender Offer were satisfied or waived, on September 15, 2025, Parent irrevocably accepted for payment all Shares validly tendered into and not validly withdrawn from the Tender Offer and paid for all such Shares in accordance with the Tender Offer.
    On September 17, 2025, following the consummation of the Tender Offer, upon the terms and conditions set forth in the Agreement and Plan of Merger, dated as of August 4, 2025, the Company filed a Certificate of Merger with the Secretary of State of the State of Delaware, pursuant to which the merger (the "Merger") became effective. In the Merger, Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation (the "Surviving Corporation"). As a result of the Merger, the Company ceased to be a publicly traded company and became a privately held company and a subsidiary of Parent.
    At the effective time of the Merger (the "Effective Time"), all 6,724,000 Shares held by the Reporting Persons and each other Share issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) an amount in cash equal to $1.95 per Share, without interest, and subject to deduction for any required tax withholding and (ii) one CVR.
    As a result of the Merger, the Common Stock will no longer be listed on any securities exchange or quotation system, including the Nasdaq Global Select Market ("Nasdaq") and the Company will cease to be a publicly traded company. On September 17, 2025 Hillevax requested that Nasdaq file an application on Form 25 with the SEC to withdraw registration of the Common Stock under the Securities Exchange Act of 1934 (the "Exchange Act"). The deregistration will become effective 90 days after the filing of Form 25, or such shorter period as may be determined by the SEC. The Company intends to suspend its reporting obligations under the Exchange Act by filing a Form 15 with the SEC in approximately 10 days following the filing of the Form 25. The Company's reporting obligations under the Exchange Act will be suspended immediately as of the filing date of the Form 15.
    The consummation of the Merger and the other transactions described in this Item 4 have resulted or will result in a number of the actions specified in clauses (a)-(j) of Item 4 of Schedule 13D with respect to the Company, including the acquisition or disposition of securities of the Company, a merger or other extraordinary transaction involving the Company, a change to the board of directors of the Company (as the surviving corporation), causing a class of securities of the Company to be delisted from a national securities exchange, a class of equity securities of the Company becoming eligible for termination of registration and a change in the Company's articles of incorporation and bylaws.

**Item 5. Interest in Securities of the Issuer**

**(a)**
As of the date of this Amendment, the Reporting Persons do not beneficially own any Common Stock.

**(b)**
As of the date of this Amendment, the Reporting Persons do not beneficially own any Common Stock.

**(c)**
Except as set forth herein, the Reporting Persons have not effected any transaction in shares of Common Stock in the past 60 days.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

The information disclosed under Item 4 of this Amendment is hereby incorporated by reference into this Item 6.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Takeda Pharmaceutical Company Limited

**Signature:** /s/ Paul Sundberg

**Name/Title:** Paul Sundberg / Authorized Signatory

**Date:** 09/19/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Takeda Vaccines Inc.

**Signature:** /s/ Max Heuer

**Name/Title:** Max Heuer / Authorized Signatory

**Date:** 09/19/2025